KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gsk (GSK) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to 30.34%.

  • Gsk's EBITDA Margin rose 279800.0% to 30.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 25.41%, marking a year-over-year increase of 53900.0%. This contributed to the annual value of 12.82% for FY2024, which is 94200.0% down from last year.
  • Per Gsk's latest filing, its EBITDA Margin stood at 30.34% for Q3 2025, which was up 279800.0% from 25.33% recorded in Q2 2025.
  • Gsk's EBITDA Margin's 5-year high stood at 31.89% during Q1 2022, with a 5-year trough of 1.99% in Q4 2021.
  • Over the past 5 years, Gsk's median EBITDA Margin value was 23.47% (recorded in 2021), while the average stood at 21.97%.
  • As far as peak fluctuations go, Gsk's EBITDA Margin plummeted by -870700bps in 2021, and later skyrocketed by 279800bps in 2025.
  • Over the past 5 years, Gsk's EBITDA Margin (Quarter) stood at 1.99% in 2021, then soared by 1100bps to 23.9% in 2022, then rose by 25bps to 29.89% in 2023, then tumbled by -31bps to 20.57% in 2024, then surged by 48bps to 30.34% in 2025.
  • Its EBITDA Margin was 30.34% in Q3 2025, compared to 25.33% in Q2 2025 and 29.48% in Q1 2025.